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Background
Identification of tumor predisposition syndromes in patients who have cancer in childhood is paramount for optimal care. A screening instrument that can help to identify such patients will facilitate physicians caring for children with cancer. The complete screening instrument should consist of a standardized series of pictures and a screening form for manifestations not visible in the pictures. Here we describe the development of such a screening form based on an international two-stage Delphi process and an initial validation of the complete instrument.
Patients and methods
We identified manifestations that may contribute to the diagnosis of a tumor predisposition syndrome through the Winter-Baraitser Dysmorphology Database and the textbook "Gorlin's Syndromes of the Head and Neck". In a two-round Delphi process, eight international content-experts scored the contribution of each of these manifestations. We performed a clinical validation of the instrument in a selected cohort of 10 pediatric cancer patients from another centre.
Results
In total, 49 manifestations were found to contribute to the diagnosis of a tumor predisposition syndrome and were included in the screening form. The pilot validation study showed that patients suspect of having a tumor predisposition syndrome were recognized. Excellent correlation for indications of patient's referral between the screening instrument and the reference standard (personal evaluation by an experienced clinical geneticist) was found.
Conclusions
The Delphi process performed by international specialists with a function as opinion leaders in their field of expertise, has led to a screening instrument for childhood cancer patients. Patients who may have a tumour predisposition syndrome and thus have an indication to be referred for further genetic analysis, can be identified using the screening instrument.
Introduction
The diagnosis of a specific tumor predisposition syndrome in patients with childhood cancer is important and clinically relevant because it can affect management. Some syndromeassociated malignancies require specific treatment strategies and some require screening for subsequent malignancies. Also, it may guide care for non-malignancy manifestations; it facilitates recurrence risk assessments and can facilitate pre-symptomatic identification of other relatives at risk for malignancies.
In previous studies, we found a substantial incidence of morphological abnormalities and recognisable clinical genetic syndromes in patients with childhood cancer. Half of these syndromes had not been recognized by the routine caregivers involved, despite expert pediatric care [1] [2] [3] . We and others recommended that all children diagnosed with a malignancy should be assessed by a clinical geneticist or a pediatrician skilled in clinical morphology 2, 4, 5 . However, in many countries there is limited access to such consultations and genetic consultations can be a low priority in acutely ill patients. A screening instrument could be a reliable aid in assuring that all childhood cancer patients at risk of having a tumor predisposition syndrome can be recognized and referred.
We argue that an easy-to-use screening form together with a standard series of 2D and 3D pictures could serve as a screening instrument. The form should easily be completed by a genetic nurse or physician involved in treatment of pediatric cancer patients. This would allow for a quick, efficient screen of completed forms accompanied by corresponding sets of pictures by a clinical geneticist who can then select those suspected to have a syndrome for a full genetic consultation. Such a screening form should be based on manifestations of known tumor predisposition syndromes, as these manifestations have already shown to indicate the cancer susceptibility. The number of tumor predisposition syndromes is large, which would result in a significant number of individual manifestations making a "non-focused' form unfeasible. Therefore, it is important to extract the most significant manifestations. Part of the manifestations in tumor predisposition syndromes will be visible on a standard set of two-dimensional (2D, overview; face in two directions; hands; feet) and three-dimensional (3D) pictures (face). The goal of this study was to identify the most sensitive manifestations of known tumor predisposition syndromes, not visible on these pictures, to include these in a screening form.
Patients and Methods
General strategy
Two important sources for the manifestations of tumor predisposition syndromes were used; a database (Winter-Baraitser Dysmorphology Database [WBDD]) 6 and a textbook (Gorlin's Syndromes of the Head and Neck) 7 . The recently published set of standardized terms to describe human morphology was used in the definite screening form [8] [9] [10] [11] [12] [13] [14] .
Expert-based opinion/Delphi process We used a two-phase Delphi process 15, 16 in which eight international specialists in this field participated. The Delphi technique is a widely accepted method for achieving convergence of opinion from experts. It is used as a method for consensus-building using a series of questionnaires in multiple consultation rounds to collect data from a panel of experts, where evidence from literature is lacking 15 . In the present study we interrogated the expert-panel regarding manifestations that only can be found in body surface examination and their contribution to the diagnosis of a tumor predisposition syndrome. In the first assessment round, eight experts gave their opinion on the relevance of the morphological manifestations from the sources WBDD and Gorlin's Syndromes of the Head and Neck. Relevance was defined as the significance or contribution of that manifestation to establishing a diagnosis of a tumor predisposition syndrome. Experts were asked to score the relevance of a manifestation on a scale from 1 to 5 (Likert scale) in which 1 was no contribution to the diagnosis of a tumor predisposition syndrome and 5 was pathognomonic for the diagnosis of a tumor predisposition syndrome. In the second assessment round, the same eight experts gave their final opinion on whether manifestations should be included in the screening form or not using a dichotomic score (in which 0 = exclude, 1 = include in screening form). The strategy of the Delphi process is provided in Figures 1 and 2 . In Supplementary data 1 more detailed information on search strategy and item selection (S1.1), search terms used (S1.2) visibility score of manifestations (S1. 3 ) and details of the Delphi process (S1.4) are given.
Pilot validation study
The list of selected manifestations based on both Delphi rounds was converted to a clinical scoring form, to which was added space for relevant general data. At this stage, WBDD nomenclature was harmonized with the Elements of Morphology terms [8] [9] [10] [11] [12] [13] [14] (Supplementary data 4, S4.1). To aid users, a booklet was composed with definitions and pictures of included manifestations (Supplementary data 4, S4.2 ). An initial clinical validation was performed using a cohort of ten selected pediatric cancer patients under care of another centre, who had a standard evaluation by a clinical geneticist not involved in the development of the screening instrument (A.W.). This cohort was composed of patients suspected to have a tumor predisposition syndrome and those not suspected to have this. The study protocol was approved by the Medical Ethics Review Committee of the Academic Medical Centre in Amsterdam. All patients and parents gave their written informed consent. Specifically for the validation process of the screening instrument an independent genetic counsellor (nurse specialized in clinical genetics) evaluated every patient and filled in the scoring form for each patient, which was complemented with the 2D and 3D picture series. Two independent clinical geneticists from another centre, one with specific expertise in dysmorphology (R.C.M.H.) and one with specific expertise in oncogenetics (C.M.A.), neither of whom had been in contact with the patients, evaluated for each patient the set of pictures and completed scoring form from the screening instrument. Based on the completed screening instrument they assessed whether referral to a clinical geneticist was indicated and classified the reason for referral (i.e., history of the patient; tumor type; family history; phenotype; or any combination of the above). Combined outcomes of both observers were compared to the reference standard: the state of the art evaluation provided by the experienced local clinical geneticist (A.W.). 
Results
Identification of tumor predisposition syndromes
Delphi round one
Decisive agreement for inclusion (median score ≥4.5, IQR 4-5) in the screening form was achieved for five manifestations (5/240, 2%) in the first round: abnormal genital pigmentation, adenoma sebaceous, axillary freckles, conjunctival teleangiectasia, neurofibromas/schwannomas. Agreement for exclusion (median score ≤2, range 1 to 5) was achieved for 181 manifestations (181/240, 75% <4.5, range 1 to 5) and these manifestations were brought to the second round of the Delphi process. Based on personal experience, the experts added 41 manifestations in the first round. Using the criteria as described earlier (manifestations found by body surface examination only or proposed by more than one expert), 7/41 manifestations were brought to the second round of the Delphi process as a separate dataset (Supplementary data 2, Table S2 .2).
Delphi round two
In the second assessment round, the same eight experts gave their final opinion on whether 61 (54 + 7) manifestations should be included in the screening form or not. Agreement for inclusion was achieved for 41 manifestations (41/61, 67%). The whole group of experts scored unanimous for 14 of the included manifestations (14/41, 34%). For 27 manifestations (27/41, 66%), the majority of experts favoured inclusion. Agreement for exclusion was achieved for 13 manifestations (13/61, 21%), the agreement of seven manifestations (7/61, 11%), was non-decisive. Of these non-decisive, three were included based on the principal investigator's assessment. 
Pilot validation study
The considered opinions of three senior clinical geneticists, on the need and indication for referral were compared in a selected cohort of 10 pediatric cancer patients. Need for referral and the reasons for referral were independently assessed based on a routine clinical genetic consultation by one geneticist and on the use of the developed screening instrument by two other geneticists. The geneticist that judged based on the routine consultation found an indication for referral ('suspect for having a tumor predisposition syndrome') in six patients, the two that judged based on the screening instrument found an indication for referral ('suspect for having a tumor predisposition syndrome') in seven patients ( Table 2 ). The reasons for referral as result of the routine consultation were also selected by the geneticists using the screening instrument. The geneticists using the instrument deduced more reasons for referral than the geneticist that judged based on the regular consultation.
Discussion
The development of a descriptive screening form is reported, and its application in a pilot study. It is anticipated that physicians or genetic nurses caring for children with cancer can easily fill out the form for each child. Completed forms accompanied by corresponding sets of pictures can then quickly and efficiently be evaluated for the need for a full genetic consultation by a clinical geneticist. Because available evidence on prevalence and recognition of tumor predisposition syndromes in patients with childhood cancer is scarce 1,2 , the value of the expert opinions elicited in the Delphi process reflects and values the clinical consensus of these international opinion leaders in their field. One of the major benefits of the Delphi method is that it offers the opportunity to obtain expert opinions without potential influence of group dynamics on individual opinions. Because we chose to give feedback on the scores anonymously, experts could see their own opinion in relation to that of other experts, making it a safe, non-judgmental environment for sharing one's opinion. Because the time frame of response was defined and standardized, this assessment gave a good reflection of the current opinion in the field of expertise at a given time point, making it more reliable.
Because all opinions were weighed equally, an assumption was that the experts participating in the Delphi process were equal in experience and knowledge. However, this may not have been the case, especially if their fields of expertise were very specialized, as in our study. For our expert panel, we chose international clinical geneticists who functioned as opinion leaders in both dysmorphology and clinical cancer genetics, or are leaders in one of the two with good experience in the other field. The number of qualified experts was relatively small, which restrained the number of experts in our panel. The small size of the expert panel could be considered as a potential limitation in the current study. However we feel that, considering the small field of study, the expert panel optimally represents international expert opinions. Other Delphi studies with similar sized expert panels have shown to yield reliable results 17, 18 .
In the present Delphi process we had to define criteria on when to include, exclude or bring a manifestation to the next Delphi round. For the first round of the Delphi we used the median scores of experts for each manifestation for inclusion and exclusion, as the median is less affected by outliers which is especially important in small groups 15 . We used a strict exclusion (median ≤2) and inclusion criterion (median ≥4.5) on the scale from 1 to 5 in the first Delphi round, so only items with strong agreement among the experts were included or excluded.
We performed a pilot validation study in an independent series of ten pediatric cancer patients and compared the clinical judgment and rationale for referral by two independent clinical geneticists using the instrument, to those of a third clinical geneticist who evaluated the patients in routine consultations. In the pilot validation study, the clinical judgments of the two clinical geneticists using the screening instrument were very similar despite their different specialisation (dysmorphology vs oncogenetics). Furthermore, this was not a randomly selected patient cohort; the cohort in this clinical validation study consisted of both patients suspect as well as patients unsuspected for having a tumor predisposition syndrome which could give rize to selection bias. In our pilot validation study, a genetic counsellor (genetic nurse) filled in the screening form; we do not expect a significant difference if the form were filled in by a pediatric oncologist or other physician involved in the care of childhood cancer patients, although this was not tested. We have not added criteria for referral indications for each tumor type and family history on our screening form: establishing reliable algorithms for the large range of tumor predisposition syndromes and the accompanying clinical spectrum with respect to tumor type and family history needs separate studies and is outside the scope of this manuscript.
We have left this consideration to the expertise of the senior clinical geneticists evaluating the results of the instrument.
The optimal validation of the instrument would be a comparative prospective study in a cohort of newly diagnosed pediatric oncology patients: referrals and reasons for referral using the screening instrument could then be compared to the routine consultation done by an experienced clinical geneticist ('reference standard'). The low incidence of tumor predisposition syndromes requires the recruitment of large numbers of patients for a considerable period of time to perform a study that potentially will yield useful results. This approach was not suitable for an initial, short-term validation. We recognize that the validation cohort is too small to support clinical implementation of the instrument. However, it does show that geneticists using the screening instrument recognize those childhood cancer patients that may have a tumor predisposition syndrome when compared to the reference standard. We can conclude that the geneticists using the instrument to evaluate the patient did not miss any significant clues for referral. This supports the design of the aforementioned, subsequent study. A prospective study, in which the feasibility and validity of the final screening instrument will be assessed, is needed to determine the diagnostic value of the instrument and is planned at present.
Conclusion
We have used a Delphi process to gather expert opinions on manifestations detectable at body surface examination that contribute to the diagnosis of a tumor predisposition syndrome. The value of the assembled expert opinions using the Delphi method is that it reflects consensus in a group of experts on a subject where evidence from the literature is lacking. This study combines data from one of the most used databases in dysmorphology and a major textbook in clinical genetics with the opinion of recognized experts in tumor predisposition syndromes. The results of the overall process formed the basis of a screening form which, when combined with the standardized series of pictures, formed a screening instrument. The screening instrument showed an excellent correlation with the reference standard in a small pilot study. The feasibility and validity of the screening instrument will be evaluated in a subsequent, prospective large study. This search strategy generated a set of manifestations associated with known tumour predisposition syndromes, which are not visible in the standard 2D or 3D picture series, and described in the correct terminology.
Supplementary data S1.2: Search terms used for the search in the WBDD
The search terms that were used for the search in the WBDD, based on the diagnostic groups of the third edition of the International Classification Supplementary data S1.3: Visibility score
For the score of theoretic visibility of manifestations on 2D and 3D picture series, the basic assumption was that the 2D picture series would comprise bilateral and frontal views of the face, ventral and dorsal views of the hands and feet and ventral and dorsal overview picture of the skin with the underpants on. For the 3D picture we assumed only the face to be captured. For both picture series we assumed optimal quality without lighting or position artefacts and ideal conditions. The theoretic visibility of the collected manifestations on the 2D and 3D picture series was independently scored by three physicians; a clinical geneticist and pediatrician (R.C.M.H.), a pediatric oncologist (J.H.M.M.) and research physician (S.M.J.H.), the latter two both trained in clinical morphology. Whenever there was discrepancy, agreement was reached by discussions.
Supplementary data 1.4: Detailed methodology of the Delphi process.
Expert-panel
The screening instrument is meant to be an aid to the anticipated users in evaluating patients for possible tumour predisposition syndromes. So the expert group should consist of colleagues that are expert in this clinical genetic field. Nine international clinical geneticists were selected based on their function as opinion leaders in their field of expertise (tumour predisposition syndromes, dysmorphology, or both). In February 2011, these nine experts were invited separately to participate in a prospective Web-based Delphi process comprising two iterative assessment rounds. One expert declined the call for personal reasons, thus eight (C.E., E.L., T.C., D.H.V., R.W., E.R.M., L.G.B. and A.V.) committed and responded to two assessment questionnaires. Experts responded independently with their identity not disclosed to the expert-panel until after the second assessment questionnaire. All eight experts completed both rounds of questionnaires. Please refer to Supplementary data 2, Table S2 .1 for more detailed information on the experience of experts.
Data collection
Delphi round one. In February 2011, the expert-panel received a first assessment questionnaire and cover letter with instructions. The questionnaire contained 240 manifestations identified in the item selection as described above (Supplementary data 3, S3.1). Experts were asked to score the relevance of each manifestation to the diagnosis of a tumor predisposition syndrome on a 5 point Likert scale (1= no contribution to 5= pathognomonic for diagnosing a tumour predisposition syndrome). A Likert-type scale is the common term for a psychometric scale, often used in questionnaires.
Delphi round two.
In the second questionnaire the inconclusive manifestations were included and presented (Supplementary data 3, S3.2). Experts were informed on the anonymised summarized scores of other experts in the panel, and were asked to give a dichotomised score (1= include in screening form and 0= exclude from screening form). From the manifestations added by the experts in the first round, only manifestations that can be found by body surface examination only or manifestations that were proposed by more than one expert were included in the second assessment questionnaire as a separate dataset and scored in an identical way, meaning a dichotomised score (1= include in screening form and 0= exclude from screening form).
Data analysis
Process data from both rounds were entered and analyzed into Excel for Windows version 2003 and PASW (IBM SPSS) version 18.0. Descriptive statistics were used to analyse responses in each round. Cut-off ranges for inclusion and exclusion in the first questionnaire were based on three possible outcomes: agreement for inclusion (median ≥ 4.5), agreement for exclusion (median ≤ 2) or agreement neutral (2 < median < 4.5). We chose for a median score because the median is less affected by the presence of an outlier in scoring which is important when collecting opinions among a small group of experts. If agreement for definitive inclusion or exclusion had been achieved for specific items after the first round, experts were not questioned further. The pre-set level of agreement in the second questionnaire was five of the eight members in agreement. For manifestations on which no agreement was achieved in the second round, the assessment of the principal investigator (RCMH) was decisive.
Supplementary data S1.5: List of 221 included syndromes from the WinterBaraitser Dysmorphology database (WBDD). += yes, -= no, +/-= dependent on other conditions (see column "Reason for inclusion or exclusion" for explanation. I: During the Delphi procedure the original terminology as used in the WBDD was maintained. For the definite screening form, terms were harmonized with the Elements of Morphology terms1-8.
Manifestation Proportion of agreement (%)
Abnormal oral mucosa (cobblestone) 100
Ambiguous/absent genitalia 100
Hemi-hypertrophy I 100
Hypertrophy of lower limb I 100
Large tongue 100
Lipomata 100
Macrocephaly 100
Mucosal neurinomas 100
Palmar pits 100
Perioral papilloma 100
Pedunculated skin lesions/skin tags 100
Photosensitivity skin 100
Scalp tumours 100 
Supplementary data 3
Supplementary data S3.1 Score form Delphi round 1
Please score (on a scale from 1 to 5) which morphological abnormalities would contribute to the diagnosis of known tumor predisposition syndromes in the first screening of a patient.
1-no contribution to diagnosis tumor predisposition syndrome 2 3 4 5-pathognomonic for diagnosis tumor predisposition syndrome 
